Creating value through strategic investments in early-stage innovative cutting-edge programs and technologies

Business Models

PRIMARY: Create, Incubate & Expand U.S. Start-ups

  • Interests in innovative preclinical programs
    • Cutting-edge/breakthrough technology platforms
    • Novel biology/pathway/targets
  • Prefer platform and pipeline portfolio opportunities than single assets

  • Open to all stages of preclinical projects but prefer those that already have a lead(s) with 1-3 years before entering clinic

ALTERNATIVE: License-in & JV

  • Single asset programs – license in for China or global rights
    • Global Rights: open to all stages of preclinical and/or early clinical projects
    • China Rights: programs that have PoC in clinic
  • Consider JV for technology platforms

OUR BUSINESS MODEL

(for newco)

target-icon-LG-wht

DEAL SOURCE

grow-icon-LG-wht

FUTURE OPTIONS

ADVANTAGES
Access to Fosun Pharma Resources:

Business & Operations
Wide Range R&D Resources & Expertise
Shared Facility & Office Space

Primary Areas of Investment

Therapeutic Areas Examples

  • CNS
  • Autoimmune disease
  • Respiratory disease
  • Metabolic disease
  • Infectious disease
  • Cancer (esp. lung, stomach, liver, esophagus)
  • Rare disease

Technologies Examples

  • Gene therapy
  • Nucleic acids/RNA therapeutics
  • Microbiome
  • Cell therapy
  • ProTAC
  • Vaccines
  • Small & large molecules

What FUSION Offers

FUNDING

  • Enhanced seed”/series-A funding for newco

EXPERIENCE

  • Broad and extensive R&D experience in discovery, preclinical and clinical development
  • Experience in large pharma and start-up companies in US
  • Interim executive leadership where needed

RESOURCES

  • Business functions (BD, legal/IP, finance, HR) shared with Fosun Pharma USA
  • Shared facility & office space
  • Operational and program management
  • Scientific committee / Network of KOLs

ACCESS TO A WIDE RANGE OF RESOURCES THROUGH FOSUN PHARMA

  • Partnership with Fosun Pharma portfolio company technology platforms (small molecules, mAb, CAR-T, stem cells, etc.)
  • Clinical development, regulatory and registration team
  • Manufacturing network (incl. large and small molecules, cell therapy, etc.)
  • Integrated healthcare system including diagnostics, medical device, hospital and clinic network
  • Distribution capabilities and market depth (largest private stake holder of Sinopharm Group) in China

Interested?

Let's get started.

Please complete and submit the contact form below.
Be sure to attach any relevant documents for review and consideration.